Exact Sciences Co. (NASDAQ:EXAS) Stake Lifted by Commerce Bank

Commerce Bank increased its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 47.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,232 shares of the medical research company’s stock after buying an additional 2,330 shares during the quarter. Commerce Bank’s holdings in Exact Sciences were worth $690,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Sittner & Nelson LLC grew its stake in Exact Sciences by 800.0% during the 2nd quarter. Sittner & Nelson LLC now owns 225 shares of the medical research company’s stock worth $28,000 after buying an additional 200 shares during the last quarter. Berman Capital Advisors LLC grew its stake in Exact Sciences by 214.9% during the 3rd quarter. Berman Capital Advisors LLC now owns 359 shares of the medical research company’s stock worth $33,000 after buying an additional 245 shares during the last quarter. Liberty Wealth Management LLC grew its stake in Exact Sciences by 21,209.5% during the 2nd quarter. Liberty Wealth Management LLC now owns 4,475 shares of the medical research company’s stock worth $36,000 after buying an additional 4,454 shares during the last quarter. Koshinski Asset Management Inc. bought a new position in Exact Sciences during the 3rd quarter worth $47,000. Finally, Itau Unibanco Holding S.A. bought a new position in Exact Sciences during the 2nd quarter worth $61,000. Hedge funds and other institutional investors own 90.22% of the company’s stock.

Shares of NASDAQ EXAS opened at $78.43 on Friday. Exact Sciences Co. has a 12 month low of $69.75 and a 12 month high of $159.54. The company has a quick ratio of 2.14, a current ratio of 2.27 and a debt-to-equity ratio of 0.55. The business has a fifty day simple moving average of $81.97 and a 200-day simple moving average of $96.01.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Monday, November 1st. The medical research company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.08). Exact Sciences had a negative net margin of 46.14% and a negative return on equity of 11.53%. The company had revenue of $456.38 million for the quarter, compared to analysts’ expectations of $429.04 million. During the same period in the prior year, the company earned ($0.36) earnings per share. Equities research analysts forecast that Exact Sciences Co. will post -3.13 EPS for the current year.

In related news, CEO Kevin T. Conroy sold 16,922 shares of the company’s stock in a transaction on Monday, November 1st. The stock was sold at an average price of $93.88, for a total transaction of $1,588,637.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.40% of the stock is currently owned by insiders.

EXAS has been the subject of a number of analyst reports. BTIG Research reduced their price target on Exact Sciences from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Wednesday, November 3rd. SVB Leerink reduced their price target on Exact Sciences from $160.00 to $140.00 and set an “outperform” rating for the company in a research report on Wednesday, November 3rd. Wells Fargo & Company reduced their price target on Exact Sciences from $120.00 to $95.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 3rd. Cowen reduced their price target on Exact Sciences from $160.00 to $135.00 and set an “outperform” rating for the company in a research report on Thursday, October 14th. Finally, Robert W. Baird reduced their price target on Exact Sciences from $125.00 to $116.00 and set an “outperform” rating for the company in a research report on Wednesday, November 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $136.64.

Exact Sciences Profile

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Recommended Story: Why does a company issue an IPO?

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.